In a research note, the investment house said that Caliper may be limited in its ability to exceed heightened expectations.
The company's stock took a hit after the investment firm downgraded it to "underweight" from "neutral."
R.W. Baird, the Cowen Group, Jefferies, and UBS each recommended Complete Genomics' stock with target share prices significantly above the company's current trading price.
The investment firm noted the "enormous" market opportunity for Exact Sciences' Cologuard test and predicted it would receive FDA clearance in 2013.
All of the banks issued favorable recommendations on the molecular diagnostics firm's stock.
The bank also placed a price target of $52 on Illumina's stock.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.